Osoresnontrine

Osoresnontrine
Clinical data
Other names	BI-409306
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 1-(Oxan-4-yl)-6-(pyridin-2-ylmethyl)-5H-pyrazolo[3,4-d]pyrimidin-4-one;
CAS Number	1189767-28-9 ;
PubChem CID	135908617 ;
UNII	O9OC34WOAY ;
Chemical and physical data
Formula	C16H17N5O2
Molar mass	311.345 g·mol−1

Last updated May 27, 2025

Osoresnontrine (BI-409306) is a phosphodiesterase 9 inhibitor in development for schizophrenia,^[1] attenuated psychosis syndrome,^[2] and Alzheimer's disease.^[3] A preclinical study suggested that it increases memory in rodents.^[4]

References

↑ Brown, David; Nakagome, Kazuyuki; Cordes, Joachim; Brenner, Ronald; Gründer, Gerhard; Keefe, Richard S E; Riesenberg, Robert; Walling, David P; Daniels, Kristen; Wang, Lara; McGinniss, Jennifer; Sand, Michael (7 March 2019). "Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial". Schizophrenia Bulletin. 45 (2): 350–359. doi: 10.1093/schbul/sby049 . PMC 6403090 . PMID 29718385.
↑ Keefe, Richard S. E.; Woods, Scott W.; Cannon, Tyrone D.; Ruhrmann, Stephan; Mathalon, Daniel H.; McGuire, Philip; Rosenbrock, Holger; Daniels, Kristen; Cotton, Daniel; Roy, Dooti; Pollentier, Stephane; Sand, Michael (October 2021). "A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale". Early Intervention in Psychiatry. 15 (5): 1315–1325. doi: 10.1111/eip.13083 . ISSN 1751-7885. PMC 8451588 . PMID 33354862.
↑ Frölich, Lutz; Wunderlich, Glen; Thamer, Claus; Roehrle, Michael; Garcia, Miguel; Dubois, Bruno (December 2019). "Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease". Alzheimer's Research & Therapy. 11 (1): 18. doi: 10.1186/s13195-019-0467-2 . PMC 6371616 . PMID 30755255.
↑ Rosenbrock, Holger; Giovannini, Riccardo; Schänzle, Gerhard; Koros, Eliza; Runge, Frank; Fuchs, Holger; Marti, Anelise; Reymann, Klaus G.; Schröder, Ulrich H.; Fedele, Ernesto; Dorner-Ciossek, Cornelia (1 December 2019). "The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents" . Journal of Pharmacology and Experimental Therapeutics. 371 (3): 633–641. doi: 10.1124/jpet.119.260059 . ISSN 0022-3565. PMID 31578258.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Brown, David; Nakagome, Kazuyuki; Cordes, Joachim; Brenner, Ronald; Gründer, Gerhard; Keefe, Richard S E; Riesenberg, Robert; Walling, David P; Daniels, Kristen; Wang, Lara; McGinniss, Jennifer; Sand, Michael (7 March 2019). "Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial". Schizophrenia Bulletin. 45 (2): 350–359. doi: 10.1093/schbul/sby049 . PMC 6403090 . PMID 29718385.

[2] Keefe, Richard S. E.; Woods, Scott W.; Cannon, Tyrone D.; Ruhrmann, Stephan; Mathalon, Daniel H.; McGuire, Philip; Rosenbrock, Holger; Daniels, Kristen; Cotton, Daniel; Roy, Dooti; Pollentier, Stephane; Sand, Michael (October 2021). "A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale". Early Intervention in Psychiatry. 15 (5): 1315–1325. doi: 10.1111/eip.13083 . ISSN 1751-7885. PMC 8451588 . PMID 33354862.

[3] Frölich, Lutz; Wunderlich, Glen; Thamer, Claus; Roehrle, Michael; Garcia, Miguel; Dubois, Bruno (December 2019). "Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease". Alzheimer's Research & Therapy. 11 (1): 18. doi: 10.1186/s13195-019-0467-2 . PMC 6371616 . PMID 30755255.

[4] Rosenbrock, Holger; Giovannini, Riccardo; Schänzle, Gerhard; Koros, Eliza; Runge, Frank; Fuchs, Holger; Marti, Anelise; Reymann, Klaus G.; Schröder, Ulrich H.; Fedele, Ernesto; Dorner-Ciossek, Cornelia (1 December 2019). "The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents" . Journal of Pharmacology and Experimental Therapeutics. 371 (3): 633–641. doi: 10.1124/jpet.119.260059 . ISSN 0022-3565. PMID 31578258.

[1]

[2]

[3]

[4]